First Time Loading...

NanoRepro AG
XETRA:NN6

Watchlist Manager
NanoRepro AG Logo
NanoRepro AG
XETRA:NN6
Watchlist
Price: 1.83 EUR -0.27% Market Closed
Updated: May 1, 2024

Profitability Summary

NanoRepro AG's profitability score is 50/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

50/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

50/100
Profitability
Score
50/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
NanoRepro AG

Revenue
90.1m EUR
Cost of Revenue
-66.3m EUR
Gross Profit
23.7m EUR
Operating Expenses
-17.2m EUR
Operating Income
6.5m EUR
Other Expenses
-2.5m EUR
Net Income
4m EUR

Margins Comparison
NanoRepro AG Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
DE
NanoRepro AG
XETRA:NN6
23.6m EUR
26%
7%
4%
US
Abbott Laboratories
NYSE:ABT
185B USD
55%
16%
14%
US
Intuitive Surgical Inc
NASDAQ:ISRG
132.2B USD
66%
25%
27%
US
Stryker Corp
NYSE:SYK
123.9B USD
64%
21%
15%
IE
Medtronic PLC
NYSE:MDT
108B USD
66%
20%
13%
US
Boston Scientific Corp
NYSE:BSX
105.6B USD
70%
17%
11%
US
Becton Dickinson and Co
NYSE:BDX
67.6B USD
41%
11%
6%
DE
Siemens Healthineers AG
XETRA:SHL
58.1B EUR
36%
10%
7%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
368.4B CNY
65%
36%
33%
US
Edwards Lifesciences Corp
NYSE:EW
50.7B USD
77%
29%
23%
US
Dexcom Inc
NASDAQ:DXCM
49B USD
64%
17%
15%
Country DE
Market Cap 23.6m EUR
Gross Margin
26%
Operating Margin
7%
Net Margin
4%
Country US
Market Cap 185B USD
Gross Margin
55%
Operating Margin
16%
Net Margin
14%
Country US
Market Cap 132.2B USD
Gross Margin
66%
Operating Margin
25%
Net Margin
27%
Country US
Market Cap 123.9B USD
Gross Margin
64%
Operating Margin
21%
Net Margin
15%
Country IE
Market Cap 108B USD
Gross Margin
66%
Operating Margin
20%
Net Margin
13%
Country US
Market Cap 105.6B USD
Gross Margin
70%
Operating Margin
17%
Net Margin
11%
Country US
Market Cap 67.6B USD
Gross Margin
41%
Operating Margin
11%
Net Margin
6%
Country DE
Market Cap 58.1B EUR
Gross Margin
36%
Operating Margin
10%
Net Margin
7%
Country CN
Market Cap 368.4B CNY
Gross Margin
65%
Operating Margin
36%
Net Margin
33%
Country US
Market Cap 50.7B USD
Gross Margin
77%
Operating Margin
29%
Net Margin
23%
Country US
Market Cap 49B USD
Gross Margin
64%
Operating Margin
17%
Net Margin
15%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
NanoRepro AG Competitors

Country Company Market Cap ROE ROA ROCE ROIC
DE
NanoRepro AG
XETRA:NN6
23.6m EUR
8%
7%
11%
23%
US
Abbott Laboratories
NYSE:ABT
185B USD
15%
8%
11%
9%
US
Intuitive Surgical Inc
NASDAQ:ISRG
132.2B USD
16%
14%
14%
19%
US
Stryker Corp
NYSE:SYK
123.9B USD
18%
8%
14%
11%
IE
Medtronic PLC
NYSE:MDT
108B USD
8%
5%
8%
6%
US
Boston Scientific Corp
NYSE:BSX
105.6B USD
9%
5%
8%
6%
US
Becton Dickinson and Co
NYSE:BDX
67.6B USD
5%
2%
5%
4%
DE
Siemens Healthineers AG
XETRA:SHL
58.1B EUR
8%
3%
7%
4%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
368.4B CNY
34%
25%
34%
42%
US
Edwards Lifesciences Corp
NYSE:EW
50.7B USD
23%
16%
23%
23%
US
Dexcom Inc
NASDAQ:DXCM
49B USD
26%
9%
15%
16%
Country DE
Market Cap 23.6m EUR
ROE
8%
ROA
7%
ROCE
11%
ROIC
23%
Country US
Market Cap 185B USD
ROE
15%
ROA
8%
ROCE
11%
ROIC
9%
Country US
Market Cap 132.2B USD
ROE
16%
ROA
14%
ROCE
14%
ROIC
19%
Country US
Market Cap 123.9B USD
ROE
18%
ROA
8%
ROCE
14%
ROIC
11%
Country IE
Market Cap 108B USD
ROE
8%
ROA
5%
ROCE
8%
ROIC
6%
Country US
Market Cap 105.6B USD
ROE
9%
ROA
5%
ROCE
8%
ROIC
6%
Country US
Market Cap 67.6B USD
ROE
5%
ROA
2%
ROCE
5%
ROIC
4%
Country DE
Market Cap 58.1B EUR
ROE
8%
ROA
3%
ROCE
7%
ROIC
4%
Country CN
Market Cap 368.4B CNY
ROE
34%
ROA
25%
ROCE
34%
ROIC
42%
Country US
Market Cap 50.7B USD
ROE
23%
ROA
16%
ROCE
23%
ROIC
23%
Country US
Market Cap 49B USD
ROE
26%
ROA
9%
ROCE
15%
ROIC
16%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More